Audit 318521

FY End
2022-06-30
Total Expended
$38.06M
Findings
4
Programs
21
Year: 2022 Accepted: 2024-09-04
Auditor: Kpmg LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

ID Ref Severity Repeat Requirement
485706 2022-001 - - A
485707 2022-002 Material Weakness - A
1062148 2022-001 - - A
1062149 2022-002 Material Weakness - A

Contacts

Name Title Type
D529MMWMNHW3 Clinton Yee Auditee
8086911000 Amy Banovich Auditor
No contacts on file

Notes to SEFA

Title: (1) Basis of Presentation Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements.
Title: (2) Indirect Cost Rate Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022.
Title: (3) Personal Protective Equipment Receipts (Unaudited) Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. QHS has received personal protective equipment totaling $93,000 at fair value in response to the COVID-19 pandemic for the year ended June 30, 2022.
Title: (4) Provider Relief Funds Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. During the year ended June 30, 2021, QHS was the recipient of funds under the CARES Act Provider Relief Fund program. In accordance with guidance provided in the OMB 2 CFR 200 Part 200 Compliance Supplement, such amounts are reflected, to the extent utilized, in the Schedule of Expenditure of Federal Awards for the year ended June 30, 2022.
Title: (5) Restatement of Schedule of Expenditures of Federal Awards Accounting Policies: The accompanying schedule of expenditures of federal awards includes the federal grant activity of The Queen’s Health Systems and its subsidiaries (QHS) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in preparation of, the basic consolidated financial statements. De Minimis Rate Used: N Rate Explanation: For the Research and Development Cluster, QHS did not elect to use the 10% de minimis indirect cost rate as discussed in the Uniform Guidance Section 200.414 as QHS has a negotiated rate with the United States Department of Health and Human Services for the year ended June 30, 2022. The schedule of expenditures of federal awards has been restated to include additional expenditures of $5,000,000 for the Provider Relief Fund (assistance listing number 93.498). These expenditures were inadvertently omitted from the schedule of expenditures of federal awards.

Finding Details

Program: HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund Federal Agency Name: U.S. Department of Health and Human Services Federal Award Number: N/A Federal Award Year: 2021 – 2022 Federal Assistance Listing Number: 93.461 Compliance Requirement: Activities Allowed or Unallowed Criteria The terms and conditions for Participation in the HRSA COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program allows for reimbursement of payment for COVID-19 testing and testing related items, COVID-19 treatment or COVID-19 vaccine administration fees as determined by the program for individuals who do not have any health care coverage at the time the services were rendered. Funds provided will not be used to reimburse expenses that have been reimbursed from other sources. Conditions Found During our testing of the internal controls and compliance over the Activities Allowed and Unallowed process, we noted controls that were designed to ensure that HRSA claims reimbursements were submitted for eligible individuals for certain locations associated with a certain urgent care subsidiary were ineffective in certain circumstances. To test the compliance of this process, we tested a total of 45 HRSA claim reimbursement transactions to ensure individuals were uninsured at the time of the service and received an allowable COVID-19 service as per the terms and conditions. We noted for a certain urgent care subsidiary, that 7 of the 8 tested claims were not eligible for reimbursement as the individual either did have insurance at the time of service or the claim was already reimbursed from other sources. The HRSA claims reimbursements associated with this certain urgent care subsidiary was $40,150 for the year ending June 30, 2022. The 7 tested claims that were not eligible for reimbursement were $100 each, which total to the $700 of questioned costs. The sample was not intended to be, and was not, a statistically valid sample. This audit finding is reported as the likely questioned costs could possibly exceed the reporting threshold of $25,000. Management is evaluating the total amount to be remitted back to HRSA. Cause The above finding was caused by a lack of adequate training and monitoring at this certain urgent care subsidiary of the personnel tasked with submitting lab requisitions for COVID-19 tests performed.Effect The schedule of expenditures of federal awards is inappropriately stated as of June 30, 2022 because ineligible costs were charged to the program. Questioned Costs $700 Recommendation We recommend that QHS implement procedures and policies to ensure that the individuals included in HRSA claim reimbursements are uninsured at time of service and that the claim has not been reimbursed from other sources. Views of Responsible Officials QHS agrees with the finding and accepts the recommendation.
Program: Provider Relief Fund Federal Agency Name: U.S. Department of Health and Human Services Federal Award Number: N/A Federal Award Year: 2021 – 2022 Federal Assistance Listing Number: 93.498 Compliance Requirement: Other – Inaccurate Reporting on the Schedule of Expenditures of Federal Awards Criteria According to 2 CFR 200.510(b), a recipient of federal awards is required to prepare a schedule of expenditures of federal awards (Schedule) for the period covered by the entity’s financial statements, which must include the total Federal awards expended as determined in accordance with 2 CFR 200.502. Additionally, CFR 200.303 requires non-Federal entities receiving federal awards to establish and maintain internal controls designed to reasonably ensure compliance with Federal laws, regulations, and program compliance requirements. Effective internal controls should include procedures to ensure federal expenditures are accurately and completely reported on the Schedule. Conditions Found QHS did not have adequate internal controls related to the reporting of expenditures on the Schedule for the Provider Relief Fund. Specifically, QHS did not have a control to reconcile the Provider Relief Funds received and submitted on the Health Resources and Services Administration (HRSA) Provider Relief Fund reporting portal to the amounts reported on the Schedule. As a result, QHS determined that $5,000,000 of Provider Relief Fund expenditures were inadvertently omitted from the June 30, 2022 Schedule. Cause In discussing the conditions with QHS management, they stated it was caused by failure to implement a reconciliation control related to the Provider Relief Funds received and submitted on the HRSA Provider Relief Fund reporting portal to the amounts reported on the SEFA. Effect Failure to establish effective internal controls regarding the financial reporting for the preparation of the Schedule may prevent QHS from completing an audit in accordance with timelines of Uniform Guidance. Questioned Costs Not applicable.Statistical Sample Not applicable. Repeat Finding This finding is not a repeat finding in the immediately prior audit. Recommendation We recommend that QHS implement a system of internal control that is designed and operating effectively to ensure the Schedule is complete and accurate. Views of Responsible Officials QHS agrees with the finding and accepts the recommendation.
Program: HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund Federal Agency Name: U.S. Department of Health and Human Services Federal Award Number: N/A Federal Award Year: 2021 – 2022 Federal Assistance Listing Number: 93.461 Compliance Requirement: Activities Allowed or Unallowed Criteria The terms and conditions for Participation in the HRSA COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program allows for reimbursement of payment for COVID-19 testing and testing related items, COVID-19 treatment or COVID-19 vaccine administration fees as determined by the program for individuals who do not have any health care coverage at the time the services were rendered. Funds provided will not be used to reimburse expenses that have been reimbursed from other sources. Conditions Found During our testing of the internal controls and compliance over the Activities Allowed and Unallowed process, we noted controls that were designed to ensure that HRSA claims reimbursements were submitted for eligible individuals for certain locations associated with a certain urgent care subsidiary were ineffective in certain circumstances. To test the compliance of this process, we tested a total of 45 HRSA claim reimbursement transactions to ensure individuals were uninsured at the time of the service and received an allowable COVID-19 service as per the terms and conditions. We noted for a certain urgent care subsidiary, that 7 of the 8 tested claims were not eligible for reimbursement as the individual either did have insurance at the time of service or the claim was already reimbursed from other sources. The HRSA claims reimbursements associated with this certain urgent care subsidiary was $40,150 for the year ending June 30, 2022. The 7 tested claims that were not eligible for reimbursement were $100 each, which total to the $700 of questioned costs. The sample was not intended to be, and was not, a statistically valid sample. This audit finding is reported as the likely questioned costs could possibly exceed the reporting threshold of $25,000. Management is evaluating the total amount to be remitted back to HRSA. Cause The above finding was caused by a lack of adequate training and monitoring at this certain urgent care subsidiary of the personnel tasked with submitting lab requisitions for COVID-19 tests performed.Effect The schedule of expenditures of federal awards is inappropriately stated as of June 30, 2022 because ineligible costs were charged to the program. Questioned Costs $700 Recommendation We recommend that QHS implement procedures and policies to ensure that the individuals included in HRSA claim reimbursements are uninsured at time of service and that the claim has not been reimbursed from other sources. Views of Responsible Officials QHS agrees with the finding and accepts the recommendation.
Program: Provider Relief Fund Federal Agency Name: U.S. Department of Health and Human Services Federal Award Number: N/A Federal Award Year: 2021 – 2022 Federal Assistance Listing Number: 93.498 Compliance Requirement: Other – Inaccurate Reporting on the Schedule of Expenditures of Federal Awards Criteria According to 2 CFR 200.510(b), a recipient of federal awards is required to prepare a schedule of expenditures of federal awards (Schedule) for the period covered by the entity’s financial statements, which must include the total Federal awards expended as determined in accordance with 2 CFR 200.502. Additionally, CFR 200.303 requires non-Federal entities receiving federal awards to establish and maintain internal controls designed to reasonably ensure compliance with Federal laws, regulations, and program compliance requirements. Effective internal controls should include procedures to ensure federal expenditures are accurately and completely reported on the Schedule. Conditions Found QHS did not have adequate internal controls related to the reporting of expenditures on the Schedule for the Provider Relief Fund. Specifically, QHS did not have a control to reconcile the Provider Relief Funds received and submitted on the Health Resources and Services Administration (HRSA) Provider Relief Fund reporting portal to the amounts reported on the Schedule. As a result, QHS determined that $5,000,000 of Provider Relief Fund expenditures were inadvertently omitted from the June 30, 2022 Schedule. Cause In discussing the conditions with QHS management, they stated it was caused by failure to implement a reconciliation control related to the Provider Relief Funds received and submitted on the HRSA Provider Relief Fund reporting portal to the amounts reported on the SEFA. Effect Failure to establish effective internal controls regarding the financial reporting for the preparation of the Schedule may prevent QHS from completing an audit in accordance with timelines of Uniform Guidance. Questioned Costs Not applicable.Statistical Sample Not applicable. Repeat Finding This finding is not a repeat finding in the immediately prior audit. Recommendation We recommend that QHS implement a system of internal control that is designed and operating effectively to ensure the Schedule is complete and accurate. Views of Responsible Officials QHS agrees with the finding and accepts the recommendation.